Unoprostone

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Unoprostone
Unoprostone.svg
Clinical data
Trade namesRescula
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Topical (eye drops)
ATC code
Legal status
Legal status
  • US: Discontinued
Pharmacokinetic data
Elimination half-life14 min
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.227.145 Edit this at Wikidata
Chemical and physical data
FormulaC22H38O5
Molar mass382.541 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Unoprostone (INN) is a prostaglandin analogue. Its isopropyl ester, unoprostone isopropyl, was marketed under the trade name Rescula for the management of open-angle glaucoma and ocular hypertension.[1]

It was approved by the Food and Drug Administration in 2000.[2]

In 2009, Sucampo Pharmaceuticals acquired the rights to the drug in the U.S. and Canada.[3]

In 2015, the drug was discontinued in the U.S.

References[edit]

  1. ^ Micromedex Detailed Consumer Information
  2. ^ "Drug Approval Package". Food and Drug Administration.
  3. ^ "Sucampo Pharmaceuticals, Inc. Acquires Rights to Rescula for U.S. and Canada" (Press release). Business Wire. April 24, 2009.